Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live

BioNTech & Moderna

6 shared events · Importance 3 · Last updated Aug 20, 2026

Importance
3
Shared Events
6
Actions
0
Sentiment
0
Live sentiment trends, interaction importance charts, and action volume tracking available on the Ergen Dashboard
70
Regulatory
BioNTech: BioNTech, a pioneer in mRNA vaccines, is positively impacted by the FDA approval, reinforcing the commercial viability of its mRNA platform.
Moderna: Moderna, a key player in mRNA vaccines, is likely to see increased investor confidence and market opportunities following the FDA's approval of an mRNA flu vaccine.
Aug 06, 2026 · 6 articles
60
Accidents
BioNTech: BioNTech is a key partner in the urgent high-level coordination meeting convened by United States — Centers for Disease Control and Prevention, potentially involved in assessing medical countermeasures for the Ebola outbreak.
Moderna: Moderna is a key partner in the urgent high-level coordination meeting convened by United States — Centers for Disease Control and Prevention, potentially involved in assessing medical countermeasures for the Ebola outbreak.
May 15, 2026 · 446 articles
55
Regulatory
BioNTech: BioNTech, a competitor in mRNA vaccines, may be spurred by Moderna's approval to advance its own flu programs.
Moderna: Moderna received its fourth FDA-approved product and first mRNA flu vaccine, boosting its commercial prospects and validating its mRNA platform.
Aug 05, 2026 · 105 articles
55
Tech
BioNTech: BioNTech is developing a similar personalized cancer vaccine with Roche. The success of Moderna and Merck's trial validates the approach and could boost BioNTech's own pipeline and investor sentiment.
Moderna: Moderna is the co-developer of the vaccine and the primary beneficiary, with its stock more than doubling and market cap surging by nearly $40 billion. The trial success validates its mRNA platform and could lead to its entry into the cancer drug market, helping offset declining COVID-19 vaccine sales.
Aug 19, 2026 · 126 articles
0
Business
BioNTech: BioNTech, in collaboration with Pfizer, halted a large U.S. trial for their updated COVID-19 vaccine due to low enrollment, potentially impacting future approvals and market share for the 50-64 age group.
Apr 01, 2026 · 6 articles
0
Domestic
Mar 16, 2026 · 22 articles
ERGEN INTELLIGENCE
Explore this relationship live

Track how BioNTech and Moderna interact across events, view sentiment trends, and discover connected entities.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.